Unrestricted Subsidiaries - Income Statement Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Schedule of Equity Method Investments
Sales	$ 1,078.0	$ 1,100.4	$ 3,098.5	$ 3,239.9
Cost of sales	704.3	1,095.5	2,849.8	3,092.7
Gross profit (loss)	373.7	4.9	248.7	147.2
Operating costs and expenses:
General and administrative	31.4	40.2	84.6	101.0
Other operating expense	2.1	6.9	11.3	17.1
Operating income (loss)	322.9	(57.1)	173.2	(14.6)
Other income (expense):
Interest expense	(53.6)	(57.7)	(165.0)	(175.3)
Gain (loss) on derivative instruments	(1.5)	15.2	(4.4)	9.6
Debt extinguishment costs	0.5		(47.2)	(0.3)
Other income	3.7	(0.3)	6.1	0.7
Total other expense	(50.9)	(42.8)	(210.5)	(165.3)
Net income (loss) before income taxes	272.0	(99.9)	(37.3)	(179.9)
Income tax benefit (expenses)	(41.4)	0.7	(40.8)	1.4
Net income (loss)	313.4	(100.6)	3.5	(181.3)
Unrestricted Subsidiaries
Schedule of Equity Method Investments
Sales	204.3	177.7	578.8	510.9
Cost of sales	245.8	180.9	672.2	544.3
Gross profit (loss)	(41.5)	(3.2)	(93.4)	(33.4)
Operating costs and expenses:
General and administrative	2.2	6.9	20.7	20.3
Other operating expense	1.7	4.0	3.6	6.8
Operating income (loss)	(45.4)	(14.1)	(117.7)	(60.5)
Other income (expense):
Interest expense	(18.8)	(25.9)	(61.7)	(72.4)
Gain (loss) on derivative instruments		(1.6)	(5.6)	4.3
Debt extinguishment costs	0.1		(47.5)
Other income	1.6	0.1	4.3	0.6
Total other expense	(17.1)	(27.4)	(110.5)	(67.5)
Net income (loss) before income taxes	(62.5)	(41.5)	(228.2)	(128.0)
Income tax benefit (expenses)	(40.1)		(40.1)
Net income (loss)	$ (22.4)	$ (41.5)	$ (188.1)	$ (128.0)